Arcutis Insider Sale, Strong Phase 2 Results, & Bright Outlook for ZORYVE
Arcutis insider sales are routine; the company’s Phase 2 success and regulatory momentum for ZORYVE signal a bright outlook for investors and clinicians.
4 minutes to read
ARCUTIS BIOTHERAPEUTICS INC